Euronext - Delayed Quote • EUR (VI5RB.NX) Follow Compare 57.60 +2.15 +(3.88%) As of December 6 at 6:30:01 PM GMT+1. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for VI5RB.NX 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Related News View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations These Stocks Are Moving the Most Today: Palantir, Nvidia, KB Home, Signet, Applied Digital, Aehr Test Systems, and More Amazon Expands Health Care Offerings Via Teladoc Partnership S&P 500 Stock Pauses Share Repurchase Plan After $4.8 Billion Acquisition Q4 2024 KB Home Earnings Call Kratos Welcomes Ranking Member Adam Smith to Glen Burnie, Maryland Facility D. Boral Capital Served as Placement Agent to Nature's Miracle Holding, Inc. Announces Up to $29.7 Million Financing VerifyMe Enters into a Warrant Inducement Transaction for $4.7 Million in Proceeds Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform Aehr Test Systems to Present Virtually at the 27th Annual Needham Growth Conference on January 16, 2025 HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year